Capelli, E, Zola, R, Lorusso, L et al. · International journal of immunopathology and pharmacology · 2010 · DOI
ME/CFS is a serious illness of unknown cause that affects about 1 in every 100 people worldwide, with women affected six times more often than men. Most people develop it between ages 20-40, and symptoms typically last several years. While doctors don't yet have a cure, treatment focuses on managing individual symptoms to help patients improve their quality of life.
This overview clarifies key diagnostic criteria and epidemiological patterns that help patients understand why their diagnosis required ruling out other conditions first. For researchers, the discussion of immune activation patterns and potential triggers (genetic, environmental, infectious) helps frame research priorities and highlights the urgent need for disease-specific biomarkers and treatments.
As an editorial review, this does not present new experimental data or prove causal mechanisms underlying ME/CFS pathology. It does not establish which specific genetic or environmental factors directly cause the disease, nor does it validate any particular treatment approach with evidence-based outcomes. The cited prevalence estimates and female-to-male ratios represent population trends but do not explain why these patterns exist.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.